These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 19593954

  • 21. Difference in statin effects on neointimal coverage after implantation of drug-eluting stents.
    Yamamoto H, Ikuta S, Kobuke K, Yasuda M, Ikeda T, Yamaji K, Ueno M, Iwanaga Y, Miyazaki S.
    Coron Artery Dis; 2014 Jun; 25(4):290-5. PubMed ID: 24614628
    [Abstract] [Full Text] [Related]

  • 22. Total cholesterol content of erythrocyte membranes is associated with the severity of coronary artery disease and the therapeutic effect of rosuvastatin.
    Zhong Y, Tang H, Zeng Q, Wang X, Yi G, Meng K, Mao Y, Mao X.
    Ups J Med Sci; 2012 Nov; 117(4):390-8. PubMed ID: 23009223
    [Abstract] [Full Text] [Related]

  • 23. [Effects of domestic rosuvastatin on coronary plaque in patients with mild-to-moderate coronary artery stenosis as evaluated by virtual histology-intravascular ultrasound].
    Yang HB, Zhao XY, Zhao YT, Zhang JY, Li L.
    Zhonghua Yi Xue Za Zhi; 2012 Jun 12; 92(22):1550-2. PubMed ID: 22944060
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis.
    McMurray JJ, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, Lindberg M, Waagstein F, Grande P, Hradec J, Kamenský G, Korewicki J, Kuusi T, Mach F, Ranjith N, Wikstrand J, CORONA Study Group.
    Circulation; 2009 Dec 01; 120(22):2188-96. PubMed ID: 19917888
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Early intervention with rosuvastatin decreases the lipid components of the plaque in acute coronary syndrome: analysis using integrated backscatter IVUS (ELAN study).
    Otagiri K, Tsutsui H, Kumazaki S, Miyashita Y, Aizawa K, Koshikawa M, Kasai H, Izawa A, Tomita T, Koyama J, Ikeda U.
    Circ J; 2011 Dec 01; 75(3):633-41. PubMed ID: 21266787
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Intensive lipid lowering therapy with titrated rosuvastatin yields greater atherosclerotic aortic plaque regression: Serial magnetic resonance imaging observations from RAPID study.
    Yogo M, Sasaki M, Ayaori M, Kihara T, Sato H, Takiguchi S, Uto-Kondo H, Yakushiji E, Nakaya K, Komatsu T, Momiyama Y, Nagata M, Mochio S, Iguchi Y, Ikewaki K.
    Atherosclerosis; 2014 Jan 01; 232(1):31-9. PubMed ID: 24401214
    [Abstract] [Full Text] [Related]

  • 32. Rosuvastatin treatment in stable chronic obstructive pulmonary disease (RODEO): a randomized controlled trial.
    Neukamm A, Høiseth AD, Einvik G, Lehmann S, Hagve TA, Søyseth V, Omland T.
    J Intern Med; 2015 Jul 01; 278(1):59-67. PubMed ID: 25495178
    [Abstract] [Full Text] [Related]

  • 33. Letter by Kaneda regarding article, "Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden".
    Kaneda H.
    Circulation; 2008 Nov 25; 118(22):e706; author reply e708-9. PubMed ID: 19029473
    [No Abstract] [Full Text] [Related]

  • 34. Achievement rates of Japan Atherosclerosis Society Guidelines 2007 LDL-cholesterol goals with rosuvastatin or atorvastatin in patients who had not achieved their goal with atorvastatin.
    Shioji K, Izuhara M, Mitsuoka H, Uegaito T, Matsuda M, Kishiwada Atherosclerosis Prevention Study (KAPS) Group.
    Cardiovasc Ther; 2014 Jun 25; 32(3):97-104. PubMed ID: 24456217
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Rosuvastatin improves impaired endothelial function, lowers high sensitivity CRP, complement and immuncomplex production in patients with systemic sclerosis--a prospective case-series study.
    Timár O, Szekanecz Z, Kerekes G, Végh J, Oláh AV, Nagy G, Csiki Z, Dankó K, Szamosi S, Németh Á, Soltész P, Szücs G.
    Arthritis Res Ther; 2013 Jun 25; 15(5):R105. PubMed ID: 24008003
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Rosuvastatin inhibits MMP-2 expression and limits the progression of atherosclerosis in LDLR-deficient mice.
    Guo H, Shi Y, Liu L, Sun A, Xu F, Chi J.
    Arch Med Res; 2009 Jul 25; 40(5):345-51. PubMed ID: 19766896
    [Abstract] [Full Text] [Related]

  • 39. Relationship between inflammation and benefits of early high-dose rosuvastatin on contrast-induced nephropathy in patients with acute coronary syndrome: the pathophysiological link in the PRATO-ACS study (Protective Effect of Rosuvastatin and Antiplatelet Therapy on Contrast-Induced Nephropathy and Myocardial Damage in Patients With Acute Coronary Syndrome Undergoing Coronary Intervention).
    Toso A, Leoncini M, Maioli M, Tropeano F, Di Vincenzo E, Villani S, Bellandi F.
    JACC Cardiovasc Interv; 2014 Dec 25; 7(12):1421-9. PubMed ID: 25523533
    [Abstract] [Full Text] [Related]

  • 40. [COSMOS (coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects) trial].
    Nohara R.
    Nihon Rinsho; 2011 Nov 25; 69 Suppl 9():341-4. PubMed ID: 22724226
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.